NasdaqGS:VYGR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. More Details


Snowflake Analysis

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Voyager Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VYGR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: VYGR's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

-0.2%

VYGR

4.5%

US Biotechs

0.3%

US Market


1 Year Return

-35.2%

VYGR

40.6%

US Biotechs

21.1%

US Market

Return vs Industry: VYGR underperformed the US Biotechs industry which returned 36.8% over the past year.

Return vs Market: VYGR underperformed the US Market which returned 19.5% over the past year.


Shareholder returns

VYGRIndustryMarket
7 Day-0.2%4.5%0.3%
30 Day-1.3%6.8%3.3%
90 Day-20.9%27.2%14.2%
1 Year-35.2%-35.2%42.9%40.6%23.8%21.1%
3 Year-58.9%-58.9%28.8%22.1%45.0%35.4%
5 Year-25.0%-25.0%51.3%39.6%127.7%102.3%

Long-Term Price Volatility Vs. Market

How volatile is Voyager Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Voyager Therapeutics undervalued compared to its fair value and its price relative to the market?

8.01x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: VYGR ($8.67) is trading above our estimate of fair value ($2.12)

Significantly Below Fair Value: VYGR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: VYGR is good value based on its PE Ratio (8x) compared to the US Biotechs industry average (33.1x).

PE vs Market: VYGR is good value based on its PE Ratio (8x) compared to the US market (21x).


Price to Earnings Growth Ratio

PEG Ratio: VYGR's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: VYGR is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (4.2x).


Next Steps

Future Growth

How is Voyager Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

-25.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VYGR's earnings are forecast to decline over the next 3 years (-25% per year).

Earnings vs Market: VYGR's earnings are forecast to decline over the next 3 years (-25% per year).

High Growth Earnings: VYGR's earnings are forecast to decline over the next 3 years.

Revenue vs Market: VYGR's revenue is expected to decline over the next 3 years (-13.5% per year).

High Growth Revenue: VYGR's revenue is forecast to decline over the next 3 years (-13.5% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VYGR is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Voyager Therapeutics performed over the past 5 years?

-1.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VYGR has high quality earnings.

Growing Profit Margin: VYGR became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: VYGR has become profitable over the past 5 years, growing earnings by -1.1% per year.

Accelerating Growth: VYGR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: VYGR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: VYGR's Return on Equity (24.1%) is considered high.


Next Steps

Financial Health

How is Voyager Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: VYGR's short term assets ($216.3M) exceed its short term liabilities ($42.1M).

Long Term Liabilities: VYGR's short term assets ($216.3M) exceed its long term liabilities ($61.5M).


Debt to Equity History and Analysis

Debt Level: VYGR is debt free.

Reducing Debt: VYGR had no debt 5 years ago.

Debt Coverage: VYGR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: VYGR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Voyager Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VYGR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VYGR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VYGR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VYGR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VYGR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

  • Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

G. Turenne (46 yo)

2.5yrs

Tenure

US$2,844,090

Compensation

Mr. G. Andre Turenne has been President, Chief Executive Officer and Director at Voyager Therapeutics, Inc. since July 16, 2018. Mr. Turenne has proven leadership, strategic vision, and a strong track reco...


CEO Compensation Analysis

Compensation vs Market: G.'s total compensation ($USD2.84M) is above average for companies of similar size in the US market ($USD1.66M).

Compensation vs Earnings: G.'s compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
G. Turenne
CEO, President & Director2.5yrsUS$2.84m0.11%
$ 373.0k
Robert Hesslein
Senior VP & General Counsel1.75yrsUS$3.34m0.017%
$ 54.5k
Omar Khwaja
Chief Medical Officer and Head of Research & Development2yrsUS$3.82m0.017%
$ 56.4k
Steven Paul
Executive Science Advisor & Director6.33yrsUS$578.18k2.3%
$ 7.5m
Krystof Bankiewicz
no datano datano data
Guangping Gao
no datano datano data
Mark Kay
no datano datano data
Phillip Zamore
no datano datano data
Allison Dorval
CFO & Principal Accounting Officer2.58yrsno data0.035%
$ 114.9k
Paul Cox
Vice President of Investor Relations1.17yrsno datano data
Michelle Smith
Chief Human Resources Officer0.33yrno datano data
Allen Nunnally
Chief Business Officer1.17yrsno datano data

1.9yrs

Average Tenure

56yo

Average Age

Experienced Management: VYGR's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
G. Turenne
CEO, President & Director2.5yrsUS$2.84m0.11%
$ 373.0k
Steven Paul
Executive Science Advisor & Director6.33yrsUS$578.18k2.3%
$ 7.5m
Dinah Sah
Consultant & Member of Scientific Advisory Board1.58yrsUS$1.81mno data
James Geraghty
Independent Director7yrsUS$601.18k0.20%
$ 664.0k
Mark Levin
Independent Director7.58yrsUS$578.18k0.098%
$ 318.2k
Patrick Aebischer
Member of Scientific Advisory Board5yrsno datano data
Glenn Pierce
Independent Director4yrsUS$583.18k0.013%
$ 43.4k
Steven Hyman
Independent Director5.33yrsUS$597.52kno data
Michael Higgins
Independent Chairman1.58yrsUS$644.18kno data
Nancy Vitale
Independent Director0.33yrno datano data
Mavis Agbandje-McKenna
Member of Scientific Advisory Boardno datano datano data
Massimo Pandolfo
Member of Scientific Advisory Boardno datano datano data

4.5yrs

Average Tenure

65yo

Average Age

Experienced Board: VYGR's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Voyager Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Voyager Therapeutics, Inc.
  • Ticker: VYGR
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$324.828m
  • Shares outstanding: 37.47m
  • Website: https://www.voyagertherapeutics.com

Number of Employees


Location

  • Voyager Therapeutics, Inc.
  • 75 Sidney Street
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VYGRNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2015
VT6DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2015
VYGR *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 2015

Biography

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company’s lead clinical candidate i...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/19 23:47
End of Day Share Price2021/01/19 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.